Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,982.40
(
0.81%
)
Dow Jones
49,149.38
(
-0.60%
)
Brent Oil
95.51
(
0.52%
)
Bitcoin
78,045.00
(
2.25%
)
News Focus
News Focus
Post# of 257433
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Bickema

Send PM Follow Ignore
Followers 19
Posts 1632
Boards Moderated 0
Alias Born 11/10/2010

Bickema

Re: DewDiligence post# 223659

Tuesday, 02/19/2019 9:27:22 AM

Tuesday, February 19, 2019 9:27:22 AM

Post# of 257433

Ocaliva (OCA) is an FXR agonist. I’ve posted on numerous occasions that I don’t think Ocaliva has what it takes to garner big sales, due to its side-effect profile, and the top-line REGENERATE data are consistent with such a viewpoint



Good news for ENTA? Can they avoid the side effects you speak of?

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today